Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients

Open access

Abstract

Background: Identifying the neural correlates of ketamine treatment may facilitate and expedite the development of novel, robust, and safe rapid-acting antidepressants. Prefrontal cortex (PFC) global brain connectivity with global signal regression (GBCr) was recently identified as a putative biomarker of major depressive disorder. Accumulating evidence have repeatedly shown reduced PFC GBCr in major depressive disorder, an abnormality that appears to normalize following ketamine treatment. Methods: Fifty-six unmedicated participants with major depressive disorder were randomized to intravenous placebo (normal saline; n = 18), ketamine (0.5 mg/kg; n = 19), or lanicemine (100 mg; n = 19). PFC GBCr was computed using time series from functional magnetic resonance imaging scans that were completed at baseline, during infusion, and at 24-h posttreatment. Results: Compared to placebo, ketamine significantly increased average PFC GBCr during infusion ( p = 0.01) and at 24-h posttreatment ( p = 0.02). Lanicemine had no significant effects on GBCr during infusion ( p = 0.45) and at 24-h posttreatment ( p = 0.23) compared to placebo. Average delta PFC GBCr (during minus baseline) showed a pattern of positively predicting depression improvement in participants receiving ketamine ( r = 0.44; p = 0.06; d = 1.0) or lanicemine ( r = 0.55; p = 0.01; d = 1.3) but not those receiving placebo ( r = −0.1; p = 0.69; d = 0.02). Follow-up vertex-wise analyses showed ketamine-induced GBCr increases in the dorsolateral, dorsomedial, and frontomedial PFC during infusion and in the dorsolateral and dorsomedial PFC at 24-h posttreatment ( corrected p < 0.05). Exploratory vertex-wise analyses examining the relationship with depression improvement showed positive correlation with GBCr in the dorsal PFC during infusion and at 24-h posttreatment but negative correlation with GBCr in the ventral PFC during infusion ( uncorrected p < 0.01). Conclusions: In a randomized placebo-controlled approach, the results provide the first evidence in major depressive disorder of ketamine-induced increases in PFC GBCr during infusion and suggest that ketamine’s rapid-acting antidepressant properties are related to its acute effects on prefrontal connectivity. Overall, the study findings underscore the similarity and differences between ketamine and another N-methyl-D-aspartate receptor antagonist while proposing a pharmacoimaging paradigm for the optimization of novel rapid-acting antidepressants prior to testing in costly clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2470547018796102

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The effects of the study drugs on average prefrontal global connectivity. Compared to placebo, ketamine significantly increased PFC GBCr during infusion (a) and at 24-h posttreatment (b). PFC GBCr changes during and following lanicemine did not significantly differ from PFC GBCr changes in the placebo group (a and b). Delta PFC GBCr (time point minus baseline) values are the estimated marginal means covarying for study site and baseline depression severity; p values reflect the results of the time effect within each group (i.e., during/post infusion vs. baseline); and *(p < 0.05) and n.s. (p > 0.05) reflect the comparison of delta PFC GBCr between groups (i.e., drug vs. placebo). PFC: prefrontal cortex; GBCr: global brain connectivity with global signal regression.
Figure 1. The effects of the study drugs on average prefrontal global connectivity. Compared to placebo, ketamine significantly increased PFC GBCr during infusion (a) and at 24-h posttreatment (b). PFC GBCr changes during and following lanicemine did not significantly differ from PFC GBCr changes in the placebo group (a and b). Delta PFC GBCr (time point minus baseline) values are the estimated marginal means covarying for study site and baseline depression severity; p values reflect the results of the time effect within each group (i.e., during/post infusion vs. baseline); and *(p < 0.05) and n.s. (p > 0.05) reflect the comparison of delta PFC GBCr between groups (i.e., drug vs. placebo). PFC: prefrontal cortex; GBCr: global brain connectivity with global signal regression.CC BY-NC · PubMed Central
Figure 2. The effects of ketamine on prefrontal global connectivity during infusion. Compared to placebo, ketamine significantly increased GBCr in the red/yellow clusters.
Figure 2. The effects of ketamine on prefrontal global connectivity during infusion. Compared to placebo, ketamine significantly increased GBCr in the red/yellow clusters.CC BY-NC · PubMed Central
Figure 3. The effects of ketamine on prefrontal global connectivity at 24-h posttreatment. Compared to placebo, ketamine significantly increased GBCr in the red/yellow clusters.
Figure 3. The effects of ketamine on prefrontal global connectivity at 24-h posttreatment. Compared to placebo, ketamine significantly increased GBCr in the red/yellow clusters.CC BY-NC · PubMed Central
Figure 4. Statistical maps examining the correlation between percentage improvement of depression and GBCr changes during infusion of ketamine (uncorrected p ≤ 0.01). Compared to placebo, treatment response—as measured by the Beck Depression Inventory at 24-h posttreatment—is associated with increased GBCr in the dorsal PFC (red/yellow), but reduced GBCr in the ventral PFC (blue).
Figure 4. Statistical maps examining the correlation between percentage improvement of depression and GBCr changes during infusion of ketamine (uncorrected p ≤ 0.01). Compared to placebo, treatment response—as measured by the Beck Depression Inventory at 24-h posttreatment—is associated with increased GBCr in the dorsal PFC (red/yellow), but reduced GBCr in the ventral PFC (blue).CC BY-NC · PubMed Central
Figure 5. Statistical maps examining the correlation between percentage improvement of depression and GBCr changes at 24-h posttreatment with ketamine (uncorrected p ≤ 0.01). Compared to placebo, treatment response—as measured by the Beck Depression Inventory at 24-h posttreatment—is associated with increased GBCr in the dorsal PFC (red/yellow).
Figure 5. Statistical maps examining the correlation between percentage improvement of depression and GBCr changes at 24-h posttreatment with ketamine (uncorrected p ≤ 0.01). Compared to placebo, treatment response—as measured by the Beck Depression Inventory at 24-h posttreatment—is associated with increased GBCr in the dorsal PFC (red/yellow).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 3

  1. Abdallah CG, Pharmacol Ther
  2. Akiki TJ, 2018, bioRxiv
  3. Davis MT, Chronic Stress

Cited by

See all 71

Metadata

Authors
Abdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F.
Affiliations
  • United States Department of Veterans Affairs (US)
  • University of Manchester (GB)
  • Department of Psychiatry, University of Manchester, Manchester, UK
Corresponding author
Abdallah, Chadi G.
Venue
Chronic Stress
Published
2018-01
Volume
2
ISSN
2470-5470 (ISSN-L)
OpenAlex
W2890782117
Cited by
70
References
49
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 14 · 2019: 12 · 2018: 4
FWCI
5.97
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Chronic Stress (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
  • National Institute of Mental Health (MH101498)
  • AstraZeneca
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
major depressive disorder, prefrontal cortex, global brain connectivity, global signal regression, NMDA receptor antagonists, rapid-acting antidepressants, treatment response biomarkers, dorsolateral prefrontal cortex, dorsomedial prefrontal cortex, ventral prefrontal cortex, ketamine infusion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients. https://app.cochat.ai/papers/10.1177/2470547018796102
The paper
Abdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F. (2018). Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients. Chronic Stress. https://doi.org/10.1177/2470547018796102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.